Printed From:

Appropriate Patients

Who is the appropriate patient for PRALUENT® (alirocumab)?

Has clinical ASCVD plus hypercholesterolemia1

OR

Has HeFH
(heterozygous familial hypercholesterolemia)1

Clinical ASCVD can be defined as one or more of the following atherosclerotic conditions2*:

  • Stroke
  • Transient ischemic attack
  • Acute coronary syndrome
  • History of MI
  • Stable or unstable angina
  • Coronary revascularization or other arterial revascularization
  • Peripheral artery disease
OR

Has HeFH
(heterozygous familial hypercholesterolemia)1

*As defined in the 2013 ACC/AHA guidelines.2

Is on maximally tolerated statin therapy1

  • Eg, rosuvastatin 20-40 mg or atorvastatin 40-80 mg
    OR
    Dose reduced if higher dose not tolerated

Requires additional LDL-C lowering1

  • ≥70 mg/dL or ≥100 mg/dL, depending on insurance (or failure to achieve plan-specified % reductions in LDL-C)
  • Lab work typically within past 30 days

Include all supporting documentation

  • Chart notes documenting criteria have been met
  • Insurance card(s)

NEED HELP? CONTACT A REP

Learn more about the appropriate patient for PRALUENT from a PRALUENT Field Representative

Contact a rep

HELP PATIENTS GET PRALUENT

Get help with prior authorization, coverage information, and more

Learn how

VIEW COPAY OFFER

Get a Copay Card for your eligible commercially insured patients

Get patient copay card

Find potential patients for PRALUENT with your EHR system

Select a category below to download a tip sheet and learn how to use your office’s existing EHR system to:

References:

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.
  2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.